Diastereoselective Synthesis of Vicinal Tertiary and N-Substituted Quaternary Stereogenic Centers by Catalytic Hydroalkylation of Dienes

Matthew J. Goldfogel and Simon J. Meek*

Department of Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3290.



SUPPORTING INFORMATION

Table of Contents

General	S1
Solvents	S2
Reagents	S2
General procedure for the hydroalkylation in Tables 1, 2 and 3	S3
Procedures and characterization of α, α -substituted oxazolone products	S3
General procedure for hydrolysis of oxazolone products in Table 4	S21
Procedure and characterization of hydrolyzed oxazolone products in Table 4	S21
Procedure and characterization for the functionalization of oxazolone products in Table 5.	S23
Procedure for exploring the effect of the alcohol additive on hydroalkylation	S24
Data table for the effect of the alcohol on diastereo- and enantioselectivity	S25
Extended data table for reaction optimization (Table 1)	S25
References	S25
NMR Spectra	S27

General: All reactions were carried out in flame or oven (140 $^{\circ}$ C) dried glassware that had been cooled under vacuum. Unless otherwise stated, all reactions were carried out under an inert N₂ atmosphere. All reagents were purged or sparged with N₂ for 20 min prior to distillation or use. All solid reagents were dried by azeotropic distillation with benzene twice prior to use. Mass spectra were obtained using a Thermo LTqFT mass spectrometer with electrospray ionization and external calibration. Proton and carbon magnetic resonance spectra (¹H NMR and ¹³C NMR) were recorded on a Bruker model DRX 400, a Bruker model AVANCE III 500, or a

Bruker AVANCE III 600 CryoProbe (¹H NMR at 400 MHz, 500 MHz or 600 MHz, ¹³C NMR at 100 or 151 MHz, ³¹P NMR at 160 or 243 MHz and ¹⁹F NMR at 376 or 564 MHz) spectrometer with solvent resonance as the internal standard (¹H NMR: CDCl₃ at 7.26 ppm, CD₂Cl₂ at 5.32 ppm, CD₃CN at 1.94 ppm; ¹³C NMR: CDCl₃ at 77.16 ppm, CD₂Cl₂ at 53.84 ppm, CD₃CN at 1.32 ppm). NMR data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, td = triplet of doublets, dt = doublet of triplets, ddd = doublet of doublets, m = multiplet, bs = broad singlet, bm = broad multiplet, etc.), and coupling constants (Hz).

The following substrates were prepared according to literature method or a modified literature method and matched reported characterization data: (*E*)-phenyl-1,3-butadiene,¹ (*E*)/(*Z*)-2-methyl-phenyl-1,3-butadiene,² (*E*)/(*Z*)-4-methyl-phenyl-1,3-butadiene,² (*E*)/(*Z*)-1-buta-1,3-dien-1-ylcylohexane,² (*E*)-4-methoxy-phenyl-1,3-butadiene,² (*E*)/(*Z*)-2-nitro-phenyl-1,3-butadiene,² (*E*)/(*Z*)-4-chloro-phenyl-1,3-butadiene,³ (*E*)/(*Z*)-4-fluoro-phenyl-1,3-butadiene,³ (*E*)-2-(buta-1,3-dien-1-yl)furan,² (*E*)-tert-butyl(hexa-3,5-dien-1-yloxy)dimethylsilane,⁴ (*E*)-dodeca-1,3-diene,⁵ 4-methyl-2-phenyloxazol-5(4H)-one,⁶ 2-phenyl-4-propyloxazol-5(4H)-one,⁷ 4-isobutyl-2-phenyloxazol-5(4H)-one,⁸ 4-phenethyl-2-phenyloxazol-5(4H)-one,⁶ sodium tetrakis[3,5-*bis*(trifluoromethyl)phenyl]borate,¹⁰ complex **34**,¹¹ complex **1**,¹² and (R,R)-TADDOL-P(O)OH.¹³

■ Solvents: Solvents were purged with argon and purified under a positive pressure of dry argon by a SG Waters purification system: dichloromethane (EMD Millipore), diethyl ether (EMD Millipore), hexanes (EMD Millipore), benzene (EMD Millipore), and THF (EMD Millipore) were passed through activated alumina columns. $CDCl_3$ and CD_2Cl_2 were purchased from Cambridge Isotope Labs, distilled over CaH_2 and stored in a dry box over activated 4 Å molecular sieves.

Reagents:

(**R**)-(+)-1,1'-**Bi**(2-napthol) was purchased from Chem Impex, dried by azeotropic distillation with benzene, stored in a dry box and used without further purification.

Chloro(1,5-cyclooctadiene)rhodium(I) dimer was purchased from Pressure Chemicals, stored in a dry box and used as received.

(S,S)-1,2-Diphenylethylenediamine was purchased from Ivy Chemicals, dried by azeotropic distillation with benzene, stored in a dry box and used without further purification.

Hexamethyldisiloxane was purchased from Sigma Aldrich, stored over 4Å molecular sieves, and used without further purification.

(S,S)-Hydrobenzoin was purchased from Sigma Aldrich, dried by azeotropic distillation with benzene, stored in a dry box and used without further purification.

Isopropanol was purchased from Fischer Scientific, distilled over CaH_2 , stored in a flask over 4Å molecular sieves and sparged with N_2 before use.

Lithium tetrafluoroborate was purchased from Sigma Aldrich, stored in the dry box after overnight heating over P_2O_5 under vacuum and used without further purification.

Lithium hexafluorophosphate was purchased from Sigma Aldrich, stored in the dry box and used as received.

Lithium *tetrakis*(**pentafluorophenyl)borate - ethyl ether complex** was purchased from Boulder Scientific, stored in a dry box, and used as received.

m-Chloroperoxybenzoic acid was purchased from Alfa-Aesar as 50-55% purity by weight and used as received without further pufication.

Methanol was purchased from Fischer Scientific, distilled over CaH_2 , stored in a flask over 4Å molecular sieves and sparged with N₂ before use.

Menthol was purchased from Sigma Aldrich, dried by azeotropic distillation with benzene, stored in a dry box and used without further purification.

Potassium carbonate was purchased from Fischer Scientific and used as received.

Silver chloride was purchased from Strem, stored in a dry box, and used without further purification.

Silver tetrafluoroborate was purchased from Strem, stored in a dry box, and used without further purification.

Sodium methoxide was purchased from Strem, stored in a dry box, and used without further purification.

Styrene was purchased from Alfa Aesar, distilled over CaH₂, and stored at -20 °C in a dry box.

t-Butanol was purchased from Sigma Aldrich, distilled over CaH_2 , stored in a flask over 4Å molecular sieves and melted before use.

■ General procedure for the (CDC)-Rh(I) catalyzed hydroalkylation of dienes with oxazalones in Tables 1, 2 and 3:

In a N₂ filled glove box, an 8 mL reaction vial with a stir bar was charged with (CDC)-Rh(I)styrene BAr^F₄, the appropriate additive and the listed diene. The appropriate solvent was added by syringe, the reaction vial capped with a Teflon® lined septum cap and the reaction allowed to stir at 22 °C for 10 minutes. The cap was removed and the nucleophile was added directly to the solution as a solid or as a liquid via syringe. The reaction was resealed with the septum cap, the lid secured with electrical tape to ensure a tight seal, and the reaction removed from the glove box. Outside the glove box, a vial of alcohol was sparged for 10 minutes with N₂ and added to the reaction via syringe under an atmosphere of N₂. The reaction was allowed to stir at the appropriate temperature for the listed time before being cooled to room temperature, unsealed, and 5 µL of hexamethyldisiloxane added as an internal standard. The solution was diluted with CDCl₃ and analyzed by NMR spectroscopy to determine the conversion and diastereoselectivity. The NMR sample was recombined with the reaction and the solvents removed *in vacuo* before being purified by SiO₂ gel chromatography. Products eluted with similar retention times in the following order: 1) the 1,4-addition products, 2) the *anti*-1,2-addition products, and 3) the *syn*-1,2-addition products.

■ Procedure and characterization for the (CDC)-Rh(I) catalyzed hydroalkylation of dienes with oxazalones in Tables 1, 2 and 3:





Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and phenylbutadiene (13.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 19:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **4** (26.0 mg, 0.085 mmol, 85% yield, >20:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.06 – 8.02 (m, 2H), 7.61 – 7.55 (m, 1H), 7.51-7.48 (m, 2H), 7.40 (d, J = 7.3 Hz, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.23 (t, J = 7.3 Hz, 1H), 6.53 (d, J = 15.9 Hz, 1H), 6.25 (dd, J = 15.9, 9.3 Hz, 1H), 2.80 (dq, J = 13.7, 6.9 Hz, 1H), 1.50 (s, 3H), 1.05 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.0, 160.1, 137.0, 132.8, 132.7, 129.3, 128.8, 128.5, 128.0, 127.5, 126.4, 125.9, 72.5, 45.1, 22.7, 15.8. **IR** (v/cm⁻¹): 3060 (w), 3028 (w), 2973 (m), 2930 (m), 2872 (w), 1821 (s), 1654 (s), 1494 (w), 1450 (m), 1320 (w), 1291 (m), 1173 (m), 1001 (s), 969 (w), 889 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₀H₂₀NO₂⁺ 306.1489, found: 306.1488.

Synthesis of 4-(E-4-(4-chlorophenyl)but-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (5).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and *p*-chloro-phenylbutadiene (16.5 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 19:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **5** (22.8 mg, 0.067 mmol, 67% yield, 19:1 dr) as a colorless oil. The product was isolated with less than 5% of the inseperable 1,4-addition product.

¹**H** NMR (600 MHz, CDCl₃) δ 8.05 – 8.02 (m, 2H), 7.61 – 7.56 (m, 1H), 7.50 (t, *J* = 7.8 Hz, 2H), 7.32 (d, *J* = 8.6 Hz, 2H), 7.27 (d, *J* = 8.5 Hz, 2H), 6.49 (d, *J* = 15.9 Hz, 1H), 6.22 (dd, *J* =

15.9, 9.3 Hz, 1H), 2.79 (dq, J = 13.7, 6.8 Hz, 1H), 1.49 (s, 3H), 1.05 (d, J = 6.8 Hz, 3H). ¹³C **NMR** (151 MHz, CDCl₃) δ 180.9, 160.4, 135.6, 132.9, 131.7, 130.2, 129.0, 128.8, 128.2, 127.7, 125.9, 72.5, 45.1, 22.8, 15.9. **IR** (v/cm⁻¹): 2972 (m), 2930 (m), 1820 (s), 1654 (s), 1492 (m), 1451 (m), 1320 (w), 1291 (m), 1173 (m), 1091 (m), 1001 (s), 971 (w), 890 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₀H₁₉ClNO₂⁺ 340.1099, found: 340.1099.

Synthesis of 4-(*E*-4-(4-fluorophenyl)but-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (6).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and p-fluoro-phenylbutadiene (29.6 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 9:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **6** (22.6 mg, 0.070 mmol, 70% yield, 6:1 dr) as a colorless oil. The product was isolated with less than 5% of the inseperable 1,4-addition product.

¹**H NMR** (600 MHz, CDCl₃) δ 8.05 – 8.01 (m, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.36 (dd, J = 8.6, 5.5 Hz, 2H), 7.00 (t, J = 8.6 Hz, 2H), 6.49 (d, J = 15.9 Hz, 1H), 6.16 (dd, J = 15.9, 9.3 Hz, 1H), 2.79 (td, J = 13.7, 6.8 Hz, 1H), 1.50 (s, 3H), 1.04 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.9, 160.2, 132.7, 131.6 129.0, 128.8, 128.0, 127.9, 127.8, 126.4, 125.9, 115.4 (d, J = 21.5 Hz) 72.4, 45.0, 22.7, 15.8. **IR** (v/cm⁻¹): 2974 (m), 2930 (m), 1821 (s), 1783 (m), 1654 (s), 1603 (w), 1508 (s), 1451 (m), 1291 (m), 1229 (m), 1158 (m), 1001 (s), 970 (w), 890 (m), 819 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₀H₁₉FNO₂⁺ 324.1394, found: 324.1395.

Synthesis of 4-(*E*-4-(4-nitrophenyl)but-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (7).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and *p*-nitro-phenylbutadiene (17.5 mg, 0.100 mmol) were combined in the glove box, solvated

with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 8:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **7** (16.8 mg, 0.048 mmol, 48% yield, 8:1 dr) as a light yellow oil.

¹**H NMR** (500 MHz, CDCl₃) δ 8.18 (d, J = 8.8 Hz, 2H), 8.06 – 8.01 (m, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.54 – 7.48 (m, 4H), 6.61 (d, J = 15.9 Hz, 1H), 6.46 (dd, J = 15.9, 9.2 Hz, 1H), 2.86 (dq, J = 13.7, 6.8 Hz, 1H), 1.51 (s, 3H), 1.08 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.6, 160.6, 147.1, 143.5, 134.7, 133.0, 131.1, 129.0, 128.2, 127.1, 125.9, 124.2, 72.3, 45.2, 22.8, 15.7. **IR** (v/cm⁻¹): 3062 (w), 2975 (m), 2932 (m), 2851 (w), 1822 (s), 1653 (s), 1596 (m), 1519 (s), 1456 (m), 1342 (s), 1290 (w), 1174 (m), 1002 (m), 891 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for $C_{20}H_{19}N_2O_4^+$ 351.1339, found: 351.1338.

Synthesis of 4-(*E*-4-(4-methoxyphenyl)but-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (8).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and *p*-methoxy-phenylbutadiene (16.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 4:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **8** (19.4 mg, 0.058 mmol, 58% yield, 7:1 dr) as a colorless oil.

anti-Diastereomer (major): [¹H NMR (600 MHz, CDCl₃) δ 8.03 (d, J = 7.2 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.49 (t, J = 7.6 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 6.47 (d, J = 15.8 Hz, 1H), 6.09 (dd, J = 15.8, 9.3 Hz, 1H), 3.80 (s, 3H), 2.82 – 2.72 (m, 1H), 1.49 (s, 3H), 1.03 (d, J = 6.8 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 181.1, 160.1, 159.1, 132.7, 132.2,

129.8, 128.8, 128.0, 127.5, 127.0, 125.9, 113.9, 72.5, 55.3, 45.1, 22.7, 15.9.] *syn*-Diastereomer (minor): [¹H NMR (600 MHz, CDCl₃) δ 8.01 (d, *J* = 7.2 Hz, 2H), 7.59 – 7.53 (m, 1H), 7.38 (t, *J* = 7.2 Hz, 2H), 7.21 (d, *J* = 8.5 Hz, 2H), 6.82 (d, *J* = 8.7 Hz, 2H), 6.28 (d, *J* = 15.9 Hz, 1H), 5.73 (dd, *J* = 16.0, 8.4 Hz, 1H), 3.80 (s, *J* = 6.8 Hz, 3H), 3.12 – 3.07 (m, 1H), 2.22 (s, 3H), 1.07 (d, *J* = 6.9 Hz, 3H).] **IR** (v/cm⁻¹): 3062 (w), 3033 (w), 2972 (m), 2933 (m), 2836 (m), 1820 (s), 1782 (m), 1654 (s), 1607 (m), 1511 (s), 1450 (m), 1297 (m), 1250 (s), 1175 (m), 1033 (m), 1001 (s), 969 (m), 889 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₂NO₃⁺ 336.1594, found: 336.1593.

Synthesis of 4-methyl-2-phenyl-4-(E-4-(o-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (9).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and *o*-methyl-phenylbutadiene (14.4 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a >20:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **9** (18.8 mg, 0.059 mmol, 59% yield, >20:1 dr) as a colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.62 – 7.53 (m, 1H), 7.51 – 7.47 (m, 2H), 7.46 – 7.39 (m, 1H), 7.20 – 7.04 (m, 3H), 6.74 (d, J = 15.7 Hz, 1H), 6.08 (dd, J = 15.7, 9.3 Hz, 1H), 2.83 (dq, J = 13.7, 6.9 Hz, 1H), 2.32 (s, 3H), 1.52 (s, 3H), 1.09 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 181.0, 160.2, 136.4, 135.4, 132.8, 131.0, 130.9, 130.3, 128.9, 128.1, 127.6, 126.2, 126.1, 126.0, 72.5, 45.4, 22.8, 19.9, 15.9. **IR** (v/cm⁻¹): 3062 (w), 3022 (w), 2973 (m), 2930 (m), 2872 (w), 1821 (s), 1653 (s), 1451 (m), 1320 (w), 1291 (m), 1173 (m), 1001 (s), 970 (w), 889 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₂NO₂⁺ 320.1645, found: 320.1645.

Synthesis of 4-methyl-2-phenyl-4-(E-4-(m-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (10).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr_{4}^{F} **1** (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol),

and *m*-methyl-phenylbutadiene (14.4 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a >20:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **10** (21.1 mg, 0.066 mmol, 66% yield, 20:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.07 – 7.98 (m, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.23-7.20 (m, 3H), 7.05 – 7.04 (m, 1H), 6.50 (d, J = 15.8 Hz, 1H), 6.23 (dd, J = 15.8, 9.3 Hz, 1H), 2.81 – 2.77 (m, 1H), 2.35 (s, 3H), 1.50 (s, 3H), 1.04 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.0, 160.1, 138.1, 136.9, 132.9, 132.7, 129.1, 128.8, 128.4, 128.3, 128.0, 127.0, 125.9, 123.61, 72.5, 45.1, 22.7, 21.4, 15.9. **IR** (v/cm⁻¹): 3060 (w), 3030 (m), 2974 (m), 2930 (m), 2872 (w), 1821 (s), 1653 (s), 1494 (m), 1451 (m), 1375 (m), 1292 (m), 1174 (m), 1093 (m), 1001 (s), 970 (w), 888 (s). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₂NO₂⁺ 320.1645, found: 320.1644.

Synthesis of 4-methyl-2-phenyl-4-(E-4-(p-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (11).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and *p*-methyl-phenylbutadiene (28.8 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 6:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **11** (28.4 mg, 0.089 mmol, 89% yield, 6:1 dr) as a colorless oil. The product was isolated with 5% of the inseperable 1,4-addition product.

anti-Diastereomer (major): [¹H NMR (500 MHz, CDCl₃) δ 8.05 – 8.02 (m, 2H), 7.59 – 7.56 (m, 1H), 7.51 – 7.48 (m, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.12 (d, *J* = 7.9 Hz, 2H), 6.50 (d, *J* = 15.8 Hz, 1H), 6.18 (dd, *J* = 15.8, 9.3 Hz, 1H), 2.83 – 2.72 (m, 1H), 2.33 (m, 3H), 1.49 (s, 3H), 1.03 (d,

J = 6.8 Hz, 3H).] *syn*-Diastereomer (minor): [¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, J = 7.1 Hz, 2H), 7.41 – 7.32 (m, 3H), 7.17 (d, J = 8.0 Hz, 2H), 7.09 (d, J = 7.9 Hz, 2H), 6.30 (d, J = 15.9 Hz, 1H), 5.82 (dd, J = 15.9, 8.4 Hz, 1H), 3.15 – 3.06 (m, 1H), 2.32 (s, 3H), 2.22 (s, 3H), 1.07 (d, J = 6.9 Hz, 3H).] ¹³C NMR (151 MHz, CDCl₃) δ 181.2, 165.6, 160.2, 159.9, 137.7, 137.6, 137.5, 134.3, 134.2, 134.0, 132.8, 132.8, 129.4, 129.4, 128.9, 128.8, 128.4, 128.3, 128.1, 126.5, 126.4, 126.3, 126.2, 126.1, 109.3, 72.6, 47.0, 45.3, 22.8, 21.3, 16.0, 15.3, 14.0. **IR** (v/cm⁻¹): 3026 (w), 2974 (m), 2930 (m), 2873 (w), 1820 (s), 1783 (m), 1653 (s), 1513 (m), 1451 (m), 1291 (m), 1173 (m), 1001 (s), 971 (m), 889 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₂NO₂⁺ 320.1645, found: 320.1646.

Synthesis of 4-(*E*-4-(furan-2-yl)but-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (12).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 2-(buta-1,3-dien-1-yl)furan (24.0 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 9:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **12** (26.9 mg, 0.091 mmol, 91% yield, 9:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.07 – 8.01 (m, 2H), 7.61 – 7.56 (m, 1H), 7.53 – 7.46 (m, 2H), 7.38 – 7.32 (m, 1H), 6.39 – 6.33 (m, 2H), 6.23 (d, J = 3.3 Hz, 1H), 6.20 (dd, J = 16.0, 9.4 Hz, 1H), 2.77 – 2.72 (m, 1H), 1.50 (s, 3H), 1.03 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.1, 160.3, 152.6, 142.0, 132.8, 128.9, 128.2, 128.2, 126.0, 121.3, 111.4, 107.7, 72.6, 44.9, 22.8, 15.9. **IR** (v/cm⁻¹): 3062 (w), 2976 (m), 2933 (w), 2874 (w), 1820 (s), 1655 (s), 1451 (m), 1291 (m), 1173 (m), 1002 (s), 887 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₁₈H₁₉NO₃⁺ 296.1287, found: 296.1282.

Synthesis of 4-(E-dodec-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (14).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr $_{4}^{F}$ **1** (8.1 mg, 0.005 mmol), LiBAr $_{4}^{F}$ (3.4 mg, 0.005 mmol), and 1,3-dodecadiene (33.3 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 µL, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 µL) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 12:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed in vacuo. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 20:1 Hex/Et₂O) to afford 14 (22.5 mg, 0.066 mmol, 66% yield, 12:1 dr) as a colorless oil. ¹**H NMR** (600 MHz, CDCl₃) δ 8.05 – 8.00 (m, 2H), 7.61 – 7.54 (m, 1H), 7.50 – 7.47 (m, 2H), 5.58 (dt, J = 13.8, 7.9 Hz, 1H), 5.40 (dd, J = 15.3, 9.1 Hz, 1H), 2.58 (dq, J = 13.8, 6.9 Hz, 1H), 2.02 - 1.99 (m, 2H), 1.47 (s, 3H), 1.34 - 1.17 (m, 12H), 0.98 (d, J = 6.9 Hz, 3H), 0.88 (t, J = 7.1Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 181.0, 159.8, 134.4, 132.6, 129.0, 128.7, 127.9, 126.0, 72.3, 44.6, 32.6, 31.9, 29.4, 29.4, 29.3, 29.1, 22.7, 22.4, 15.6, 14.1. **IR** (v/cm⁻¹): 3063 (w), 3033 (w), 2957 (w), 2926 (s), 2854 (m), 1822 (s), 1654 (s), 1452 (m), 1321 (w), 1292 (m), 1175 (m), 1000 (s), 972 (w), 886 (m). **HRMS** (ES⁺) $[M-H]^+$ calcd for $C_{22}H_{32}NO_2^+$ 342.2428, found: 342.2428.

Synthesis of 4-(E-4-cyclohexylbut-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (15).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and cyclohexylbutadiene (27.2 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 3:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents

removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 20:1 Hex/Et₂O) to afford **15** (13.3 mg, 0.043 mmol, 43% yield, 6:1 dr) as a colorless oil. *anti*-Diastereomer (major): [¹H NMR (600 MHz, CDCl₃) δ 8.00 – 7.98 (m, 2H), 7.58 – 7.54 (m, 1H), 7.50 – 7.45 (m, 2H), 5.51 (dd, *J* = 15.0, 6.9 Hz, 1H), 5.33 (ddd, *J* = 15.4, 9.1, 1.1 Hz, 1H), 2.57 – 2.51 (m, 1H), 1.95 – 1.90 (m, 1H), 1.67 – 1.56 (m, 6H), 1.45 (s, 3H), 1.28 – 1.13 (m, 2H), 1.07 – 0.98 (m, 2H), 0.96 (d, *J* = 6.8 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 181.2, 159.9, 140.4, 132.7, 128.9, 128.1, 128.0, 126.6, 126.2, 72.5, 44.8, 40.8, 33.2, 33.1, 26.3, 26.1, 22.4, 15.8] *syn*-Diastereomer (minor): [¹H NMR (600 MHz, CDCl₃) δ 8.01 – 7.98 (m, 2H), 7.58 – 7.54 (m, 1H), 7.50 – 7.46 (m, 2H), 5.48 (dd, *J* = 14.5, 6.9 Hz, 1H), 5.23 (ddd, *J* = 15.4, 9.0, 1.1 Hz, 1H), 2.57 – 2.51 (m, 1H), 1.88 – 1.81 (m, 1H), 1.69 – 1.54 (m, 6H), 1.47 (s, 3H), 1.27 – 1.13 (m, 2H), 1.11 (d, *J* = 6.9 Hz, 3H), 1.09 – 0.98 (m, 2H). ¹³C NMR (151 MHz, CDCl₃) δ 180.7, 159.9, 140.1, 132.7, 128.9, 128.1, 128.0, 126.4, 126.2, 73.1, 44.5, 40.6, 33.2, 33.0, 26.2, 26.0, 22.1, 15.1.] **IR** (v/cm⁻¹): 2973 (w), 2925 (s), 2851 (m), 1822 (s), 1653 (s), 1508 (s), 1457 (m), 1291 (m), 1228 (m), 1158 (m), 1001 (s), 890 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₀H₂₅NO₂⁺ 312.1964, found: 312.1958.

Synthesis of 4-(*E*-6-((tert-butyldimethylsilyl)oxy)hex-3-en-2-yl)-4-methyl-2-phenyloxazol-5(4H)-one (16).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and *tert*-butyl(hexa-3,5-dien-1-yloxy)dimethylsilane (42.5 mg, 0.200 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (17.5 mg, 0.100 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 4:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 20:1 Hex/Et₂O) to afford **16** (26.4 mg, 0.068 mmol, 68% yield, 4:1 dr) as a colorless oil.

anti-Diastereomer (major): [¹H NMR (600 MHz, CDCl₃) δ 8.02 – 7.99 (m, 2H), 7.60 – 7.53 (m, 1H), 7.51 – 7.46 (m, 2H), 5.64 – 5.56 (m, 1H), 5.48 (dd, J = 15.4, 9.0 Hz, 1H), 3.58 (t, J = 6.8 Hz, 2H), 2.68 – 2.50 (m, 1H), 2.30 – 2.20 (m, 2H), 1.46 (s, 3H), 0.96 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 6H). ¹³C NMR (151 MHz, CDCl₃) δ 181.2, 160.0, 132.8, 131.2, 130.6, 128.9, 128.1, 126.1, 72.4, 63.1, 44.8, 36.3, 26.1, 22.6, 18.5, 15.8, -5.1.] *syn*-Diastereomer

(minor): [¹H NMR (600 MHz, CDCl₃) δ 8.01 – 7.98 (m, 2H), 7.60 – 7.53 (m, 1H), 7.51 – 7.46 (m, 2H), 5.61 – 5.53 (m, 1H), 5.38 (dd, *J* = 15.4, 9.0 Hz, 1H), 3.56 – 3.52 (m, 2H), 2.68 – 2.50 (m, 1H), 2.19 – 2.15 (m, 2H), 1.48 (s, 3H), 1.11 (d, *J* = 6.9 Hz, 3H), 0.85 (s, 9H), 0.00 (s, 3H), 0.00 (s, 3H).] **IR** (v/cm⁻¹): 2954 (m), 2929 (s), 2857 (m), 1823 (s), 1653 (s), 1452 (m), 1292 (m), 1255 (m), 1174 (m), 1099 (s), 1002 (s), 886 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₂H₃₄NO_{3Si}⁺ 388.2308, found: 388.2302.

Synthesis of 4-(E-4-(furan-2-yl)but-3-en-2-yl)-2-phenyl-4-propyloxazol-5(4H)-one (17).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 2-(buta-1,3-dien-1-yl)furan (12.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 2-phenyl-4-propyloxazol-5(4H)-one (30.5 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 6:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **17** (28.8 mg, 0.089 mmol, 89% yield, 6:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.05 – 8.03 (m, 2H), 7.60 – 7.56 (m, 1H), 7.52 – 7.48 (m, 2H), 7.34 (d, J = 1.5 Hz, 1H), 6.37 (dd, J = 3.3, 1.8 Hz, 1H), 6.34 (d, J = 15.9 Hz, 1H), 6.24 – 6.18 (m, 2H), 2.76 (dq, J = 9.1, 6.8 Hz, 1H), 2.00 – 1.92 (m, 1H), 1.84 – 1.76 (m, 1H), 1.27 – 1.16 (m, 1H), 1.16 – 1.07 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.3 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.7, 160.4, 152.6, 141.9, 132.8, 128.9, 128.5, 128.2, 125.9, 120.9, 111.4, 107.6, 76.9, 44.7, 38.3, 17.4, 16.0, 14.0. **IR** (ν /cm⁻¹): 3446 (br, w), 2964 (s), 2933 (m), 2874 (m), 1811 (s), 1653 (s), 1493 (m), 1452 (m), 1320 (m), 1293 (m), 1163 (m), 1020 (m), 944 (m), 883 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₀H₂₂NO₃⁺ 324.1600, found: 324.1610.

Synthesis of 4-(E-dodec-3-en-2-yl)-2-phenyl-4-propyloxazol-5(4H)-one (18).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 1,3-dodecadiene (16.6 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 2-phenyl-4-propyloxazol-5(4H)-one (30.5 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 7:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 40:1 Hex/Et₂O) to afford **18** (20.3 mg, 0.055 mmol, 55% yield, 7:1 dr) as a colorless oil. ¹H NMR (600 MHz, CDCl₃) δ 8.04 – 7.98 (m, 2H), 7.61 – 7.53 (m, 1H), 7.50 – 7.47 (m, *J* = 7.5,

4.1, 2.5 Hz, 2H), 5.59 – 5.50 (m, 1H), 5.42 – 5.37 (m, 1H), 2.65 – 2.53 (m, 1H), 2.02 – 1.98 (m, 2H), 1.95 – 1.88 (m, 1H), 1.78 (ddd, J = 13.7, 12.1, 4.8 Hz, 1H), 1.35 – 1.16 (m, 13H), 1.17 – 1.05 (m, 1H), 0.95 (d, J = 6.9 Hz, 3H), 0.87 (t, J = 7.2 Hz, 6H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.8, 160.1, 134.1, 132.7, 129.4, 128.9, 128.1, 126.1, 76.7, 44.5, 38.1, 32.7, 32.0, 29.6, 29.5, 29.4, 29.3, 22.8, 17.5, 15.9, 14.3, 14.1. **IR** (v/cm⁻¹): 2960 (m), 2926 (s), 2873 (w), 2854 (m), 1812 (s), 1654 (s), 1452 (m), 1321 (m), 1293 (m), 1165 (w), 1040 (m), 1020 (m), 942 (m), 881 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₄H₃₆NO₂⁺ 370.2746, found: 370.2751.

Synthesis of 2-phenyl-4-propyl-4-(E-4-(o-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (19).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and *o*-methyl-phenylbutadiene (14.4 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 2-phenyl-4-propyloxazol-5(4H)-one (30.5 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 10:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **19** (19.8 mg, 0.057 mmol, 57% yield, 10:1 dr) as a colorless oil. The product was isolated with less than 5% of the inseperable 1,4-addition product.

¹**H NMR** (500 MHz, CDCl₃) δ 8.06 – 8.02 (m, 2H), 7.61 – 7.55 (m, 1H), 7.52 – 7.47 (m, 2H), 7.48 – 7.43 (m, 1H), 7.20 – 7.12 (m, 3H), 6.72 (d, J = 15.7 Hz, 1H), 6.10 (dd, J = 15.7, 9.4 Hz, 1H), 2.85 (dq, J = 9.1, 6.8 Hz, 1H), 2.61 – 2.47 (m, 1H), 2.32 (s, 3H), 1.96 (ddd, J = 13.5, 12.4, 4.6 Hz, 1H), 1.85 (ddd, J = 13.7, 12.1, 4.9 Hz, 1H), 1.77 – 1.63 (m, 1H), 1.29 – 1.10 (m, 2H), 1.06 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.3 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.71, 160.31, 136.32, 135.38, 132.78, 131.14, 130.50, 130.34, 128.92, 128.12, 127.52, 126.19, 125.95, 125.93, 76.75, 45.16, 38.34, 19.94, 17.44, 16.00, 14.04. **IR** (v/cm⁻¹): 3062 (w), 3022 (w), 2963 (s), 2932 (w), 2874 (m), 1812 (s), 1782 (m), 1653 (s), 1456 (m), 1292 (m), 1162 (m), 1020 (m), 944 (m), 882 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₃H₂₆NO₂⁺ 348.1964, found: 348.1971.

Synthesis of 4-(E-4-(furan-2-yl)but-3-en-2-yl)-4-isobutyl-2-phenyloxazol-5(4H)-one (20).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 2-(buta-1,3-dien-1-yl)furan (12.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-isobutyl-2-phenyloxazol-5(4H)-one (32.6 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 19:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **20** (32.4 mg, 0.096 mmol, 96% yield, 19:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.06 – 8.02 (m, 2H), 7.61 – 7.56 (m, 1H), 7.50 (t, J = 7.7 Hz, 2H), 7.34 (d, J = 1.5 Hz, 1H), 6.36 (dd, J = 3.2, 1.8 Hz, 1H), 6.31 (d, J = 15.9 Hz, 1H), 6.22 (d, J = 3.2 Hz, 1H), 6.16 (dd, J = 15.9, 9.3 Hz, 1H), 2.71 (dq, J = 9.1, 6.8 Hz, 1H), 2.05 (dd, J = 14.2, 5.8 Hz, 1H), 1.76 (dd, J = 14.2, 6.9 Hz, 1H), 1.56 – 1.47 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.84 (d, J = 6.7 Hz, 3H), 0.83 (d, J = 6.6 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.2, 160.1, 152.6, 141.9, 132.8, 128.9, 128.5, 128.1, 126.0, 121.1, 111.4, 107.6, 76.1, 45.9, 44.8, 25.2, 24.2, 23.4, 15.6. **IR** (v/cm⁻¹): 2961 (s), 2934 (w), 2908 (w), 2873 (m), 1812 (s), 1653 (s), 1456 (m), 1319 (w), 1291 (m), 1153 (m), 1022 (m), 961 (m), 882 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₄NO₃⁺ 338.1756, found: 338.1763.

Synthesis of 4-(E-dodec-3-en-2-yl)-4-isobutyl-2-phenyloxazol-5(4H)-one (21).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 1,3-dodecadiene (16.6 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-isobutyl-2-phenyloxazol-5(4H)-one (32.6 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 8:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 40:1 Hex/Et₂O) to afford **21** (19.6 mg, 0.051 mmol, 51% yield, 8:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.04 – 7.98 (m, 2H), 7.60 – 7.55 (m, 1H), 7.51 – 7.48 (m, 2H), 5.57 – 5.46 (m, 1H), 5.37 – 5.29 (m, 1H), 2.58 – 2.53 (m, 1H), 2.07 – 1.99 (m, 1H), 1.99 – 1.92 (m, 2H), 1.80 – 1.64 (m, 1H), 1.61 – 1.46 (m, 1H), 1.33 – 1.13 (m, 13H), 0.97 (d, J = 6.8 Hz, 2H), 0.89 – 0.83 (m, 6H), 0.82 (d, J = 6.6 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.3, 159.7, 134.5, 132.6, 129.3, 128.9, 128.0, 126.2, 75.9, 45.7, 44.6, 32.7, 32.0, 29.6, 29.5, 29.4, 29.2, 25.2, 24.3, 23.2, 22.8, 15.4, 14.3. **IR** (v/cm⁻¹): 2957 (m), 2925 (s), 2871 (w), 2854 (m), 1813 (s), 1654 (s), 1452 (m), 1320 (w), 1292 (m), 1160 (w), 1023 (m), 954 (m), 881 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₅H₃₈NO₂⁺ 384.2903, found: 384.2905.

Synthesis of 4-isobutyl-2-phenyl-4-(E-4-(o-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (22).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and *o*-methyl-phenylbutadiene (14.4 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-isobutyl-2-phenyloxazol-5(4H)-one (32.6 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 10:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents

removed *in vacuo*. The resulting oil was purified by SiO_2 gel column chromatography (40:1 Hex/Et₂O) to afford **22** (32.2 mg, 0.089 mmol, 89% yield, 8:1 dr) as a colorless oil. The product was isolated with less than 5% of the inseperable 1,4-addition product.

¹**H NMR** (600 MHz, CDCl₃) δ 8.05 – 8.01 (m, 2H), 7.60 – 7.55 (m, 1H), 7.51 – 7.48 (m, 2H), 7.45 – 7.40 (m, 1H), 7.18 – 7.10 (m, 3H), 6.69 (d, J = 15.7 Hz, 1H), 6.05 (dd, J = 15.7, 9.4 Hz, 1H), 2.80 (dq, J = 13.6, 6.8 Hz, 1H), 2.30 (s, 3H), 2.07 (dd, J = 14.2, 5.7 Hz, 1H), 1.81 (dd, J =14.2, 7.0 Hz, 1H), 1.58 – 1.51 (m, 1H), 1.07 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 181.2, 160.0, 136.4, 135.4, 132.7, 131.2, 130.8, 130.3, 128.9, 128.1, 127.5, 126.2, 126.1, 126.0, 76.0, 46.3, 44.8, 25.2, 24.2, 23.4, 19.9, 15.6. **IR** (v/cm⁻¹): 3062 (w), 3021 (w), 2960 (s), 2872 (m), 1812 (s), 1781 (m), 1653 (s), 1452 (m), 1292 (m), 1159 (m), 1023 (m), 956 (m), 882 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₄H₂₈NO₂⁺ 362.2120, found: 362.2123.





Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 2-(buta-1,3-dien-1-yl)furan (12.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-phenethyl-2-phenyloxazol-5(4H)-one (39.8 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 5:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **23** (22.0 mg, 0.057 mmol, 57% yield, >20:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.10 – 8.04 (m, 2H), 7.60 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.33 (d, J = 1.3 Hz, 1H), 7.22 (t, J = 7.5 Hz, 2H), 7.15 (t, J = 7.4 Hz, 1H), 7.12 (d, J = 7.1 Hz, 2H), 6.35 (dd, J = 3.2, 1.8 Hz, 1H), 6.31 (d, J = 15.9 Hz, 1H), 6.24 – 6.17 (m, 2H), 2.80 (dq, J = 13.6, 6.8 Hz, 1H), 2.53 – 2.48 (m, 1H), 2.42 – 2.37 (m, 1H), 2.32 – 2.27 (m, 1H), 2.16 – 2.11 (m, 1H), 1.04 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.5, 160.8, 152.5, 141.9, 140.6, 132.9, 129.0, 128.6, 128.6, 128.2, 128.2, 126.3, 125.8, 121.1, 111.4, 107.8, 76.6, 44.9, 38.1, 30.6, 16.0. **IR** (v/cm⁻¹): 3063 (w), 3029 (m), 2966 (m), 2929 (m), 2873 (w), 1816 (s), 1653 (s), 1455 (m), 1320 (w), 1292 (m), 1059 (w), 997 (m), 877 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₅H₂₄NO₃⁺ 386.1756, found: 386.1761.

Synthesis of 4-(*E*-dodec-3-en-2-yl)-4-phenethyl-2-phenyloxazol-5(4H)-one (24).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 1,3-dodecadiene (16.6 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-phenethyl-2-phenyloxazol-5(4H)-one (39.8 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 7:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (100% Hex to 40:1 Hex/Et₂O) to afford **24** (9.1 mg, 0.021 mmol, 21% yield, 8:1 dr) as a colorless oil.

¹**H NMR** (500 MHz, CDCl₃) δ 8.05 – 8.01 (m, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.23 (d, J = 7.5 Hz, 2H), 7.16 (t, J = 7.4 Hz, 1H), 7.13 (d, J = 7.1 Hz, 2H), 5.59 – 5.50 (m, 1H), 5.40 (dd, J = 15.3, 9.1 Hz, 1H), 2.65 (dq, J = 13.8, 6.9 Hz, 1H), 2.56 – 2.50 (m, 1H), 2.43 – 2.37 (m, 1H), 2.31 – 2.22 (m, 1H), 2.16 – 2.09 (m, 1H), 1.98 (q, J = 6.8 Hz, 2H), 1.33 – 1.14 (m, 12H), 0.98 (d, J = 6.8 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.5, 160.4, 140.9, 134.4, 132.8, 129.6, 129.1, 128.9, 128.6, 128.1, 126.3, 126.0, 76.4, 44.5, 37.8, 32.7, 32.1, 30.5, 29.6, 29.5, 29.4, 29.3, 22.8, 15.8, 14.3. **IR** (v/cm⁻¹): 3437 (br, m), 2957 (w), 2925 (s), 2854 (m), 1818 (s), 1653 (s), 1455 (m), 1321 (w), 1292 (m), 1059 (m), 995 (m), 877 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₉H₃₈NO₂⁺ 432.2903, found: 432.2906.

Synthesis of 4-phenethyl-2-phenyl-4-(E-4-(o-tolyl)but-3-en-2-yl)oxazol-5(4H)-one (25).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and *o*-methyl-phenylbutadiene (14.4 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-phenethyl-2-phenyloxazol-5(4H)-one (39.8 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂

sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 10:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **25** (20.5 mg, 0.050 mmol, 50% yield, 10:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.08 – 8.05 (m, 2H), 7.62 – 7.58 (m, 1H), 7.53 – 7.50 (m, 2H), 7.47 – 7.43 (m, 1H), 7.24 – 7.21 (m, 2H), 7.18 – 7.09 (m, 6H), 6.71 (d, J = 15.7 Hz, 1H), 6.11 (dd, J = 15.7, 9.4 Hz, 1H), 2.94 – 2.85 (m, 1H), 2.58 – 2.50 (m, 1H), 2.46 – 7.41 (m, 1H), 2.34 – 2.29 (m, 1H), 2.28 (s, 3H), 2.23 – 2.15 (m, 1H), 1.09 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 180.4, 160.7, 140.6, 136.2, 135.4, 132.9, 130.8, 130.7, 130.4, 129.0, 128.6, 128.5, 128.2, 127.6, 126.3, 126.2, 125.9, 125.9, 76.4, 45.2, 38.0, 30.5, 19.9, 16.0. **IR** (v/cm⁻¹): 3062 (w), 3027 (m), 2967 (m), 2929 (m), 2866 (w), 1816 (s), 1653 (s), 1496 (w), 1456 (m), 1292 (m), 1118 (m), 1058 (m), 996 (s), 877 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₈H₂₈NO₂⁺ 410.2121, found: 410.2124.

Synthesis of 4-(E-4-(furan-2-yl)but-3-en-2-yl)-4-phenethyl-2-phenyloxazol-5(4H)-one (26).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and 2-(buta-1,3-dien-1-yl)furan (12.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-allyl-2-phenyloxazol-5(4H)-one (30.2 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 70 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 5:1 mixture of the anti:syn diastereomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (40:1 Hex/Et₂O) to afford **26** (9.0 mg, 0.028 mmol, 28% yield, 9:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 8.04 – 8.03 (m, 2H), 7.62 – 7.57 (m, 1H), 7.51 – 7.48 (m, 2H), 7.35 (d, J = 1.5 Hz, 1H), 6.39 – 6.32 (m, 2H), 6.25 – 6.19 (m, 2H), 5.60 – 5.53 (m, 1H), 5.14 (d, J = 17.0, 1H), 5.06 (d, J = 10.2 Hz, 1H), 2.80 (dq, J = 9.2, 6.9 Hz, 1H), 2.75 (dd, J = 13.7, 6.4 Hz, 1H), 2.53 (dd, J = 13.8, 8.3 Hz, 1H), 1.02 (d, J = 6.8 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 179.9, 160.5, 152.5, 142.0, 132.8, 131.0, 128.9, 128.2, 128.2, 125.9, 121.2, 120.7, 111.4, 107.8,

44.3, 40.5, 16.0. **IR** (v/cm⁻¹): 2968 (m), 2927 (m), 1815 (s), 1654 (s), 1451 (m), 1322 (m), 1292 (m), 1152 (w), 1055 (m), 998 (m), 964 (m), 927 (m). **HRMS** (ES⁺) $[M-H]^+$ calcd for $C_{20}H_{20}NO_3^+$ 322.1443, found: 322.1438.

Synthesis of 4-isobutyl-2-phenyl-4-(E-4-phenylbut-3-en-2-yl)oxazol-5(4H)-one (27).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and phenylbutadiene (13.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-isobutyl-2-phenyloxazol-5(4H)-one (32.6 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 2:1 mixture of the anti:syn diastereomers and a 20:1 mixture of the (1,2):(1,4) regioisomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford **27** (33.4 mg, 0.0960 mmol, 96% yield, 2:1 dr, 19:1 (1,2):(1,4)) as a colorless oil.

anti-Diastereomer (major): [¹H NMR (600 MHz, CDCl₃) δ 8.05 – 8.04 (m, 2H), 7.60 – 7.56 (m, 1H), 7.52 – 7.49 (m, 2H), 7.39 – 7.37 (m, 2H), 7.32 – 7.30 (m, 2H), 7.25 – 7.21 (m, 1H), 6.49 (d, J = 15.9 Hz, 1H), 6.21 (dd, J = 15.9, 9.3 Hz, 1H), 2.77 (dq, J = 9.1, 6.8 Hz, 1H), 2.43 (dd, J = 7.0, 4.3 Hz, 1H), 2.05 (dd, J = 14.2, 5.8 Hz, 1H), 1.78 (dd, J = 14.2, 6.9 Hz, 1H), 1.55 -1.49 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 0.83 (t, J = 7.0 Hz, 6H).] syn-Diastereomer (minor): [¹H **NMR** (600 MHz, CDCl₃) δ 8.05 – 8.03 (m, 2H), 7.60 – 7.57 (m, 1H), 7.51 – 7.49 (m, 2H), 7.39 – 7.36 (m, 2H), 7.28 - 7.23 (m, 2H), 7.23 - 7.18 (m, 1H), 6.35 (d, J = 15.9 Hz, 1H), 5.91 (dd, J = 15.9 Hz, 1H), 515.9, 8.5 Hz, 1H), 3.18 - 3.11 (m, 1H), 2.43 (dd, J = 7.0, 4.3 Hz, 1H), 2.15 - 2.08 (m, 1H), 2.04(dd, J = 14.2, 5.8 Hz, 1H), 1.77 (dd, J = 14.3, 6.8 Hz, 1H), 1.09 (d, J = 6.9 Hz, 3H), 0.90 (d, J = 6.7 Hz, 3H), 0.88 (d, J = 6.7 Hz, 3H).] (1,4)-Regioisomer (minor): [¹H NMR (600 MHz, $CDCl_3$) δ 7.99 – 7.96 (m, 2H), 7.56 – 7.54 (m, 1H), 7.50 – 7.46 (m, 2H), 7.38 – 7.32 (m, 2H), 7.30 - 7.26 (m, 2H), 7.23 - 7.18 (m, 1H), 5.69 - 5.58 (m, 2H), 3.61 (d, J = 8.9 Hz, 1H), 2.49 (dd, J = 7.0, 2.0 Hz, 1H), 2.24 - 2.16 (m, 1H), 1.68 (dd, J = 14.3, 5.9 Hz, 1H), 1.60 (d, J = 5.1 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H).] ¹³C NMR (151 MHz, CDCl₃) δ 181.1, 165.5, 162.2, 159.9, 138.0, 137.0, 136.8, 133.8, 132.6, 129.7, 129.1, 128.8, 128.7, 128.5, 128.5, 128.3, 128.0, 127.6, 127.5, 127.3, 126.5, 126.4, 126.3, 125.9, 109.2, 76.0, 47.0, 46.0, 44.7, 36.5,

26.3, 25.1, 24.1, 23.3, 22.6, 22.4, 15.5, 15.2. **IR** (v/cm⁻¹): 3028 (w), 2960 (s), 2934 (w), 2872 (m), 1812 (s), 1781 (m), 1653 (s), 1495 (m), 1450 (m), 1320 (w), 1292 (m), 1158 (m), 1023 (w), 960 (s), 882 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for $C_{23}H_{26}NO_2^+$ 348.1964, found: 348.1958.

Synthesis of 2-(4-chlorophenyl)-4-methyl-4-(E-4-phenylbut-3-en-2-yl)oxazol-5(4H)-one (28).



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr^F₄ **1** (8.1 mg, 0.005 mmol), LiBAr^F₄ (3.4 mg, 0.005 mmol), and phenylbutadiene (13.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 μ L, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 2-(4-chlorophenyl)-4-methyloxazol-5(4H)-one (31.4 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. Outside the glove box, N₂ sparged isopropanol (5 μ L) was added and the reaction allowed to stir at 50 °C for 48 h. The reaction was cooled to room temperature and 5 μ L of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and analyzed by NMR spectroscopy as a 3:1 mixture of the anti:syn diastereomers and a 11:1 mixture of the (1,2):(1,4) regioisomers. The NMR sample was recombined with the reaction and the solvents removed *in vacuo*. The resulting oil was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O to 10:1 Hex/Et₂O) to afford **28** (24.1 mg, 0.0710 mmol, 71% yield, 3:1 dr, 11:1 (1,2):(1,4)) as a colorless oil.

anti-Diastereomer (major): [¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.95 (m, 2H), 7.51 – 7.44 (m, 2H), 7.42 – 7.37 (m, 2H), 7.33 – 7.30 (m, 2H), 7.29 – 7.22 (m, 1H), 6.53 (d, *J* = 15.9 Hz, 1H), 6.22 (dd, *J* = 15.9, 9.3 Hz, 1H), 2.80 (dq, *J* = 13.7, 6.9 Hz, 1H), 1.50 (s, 3H), 1.04 (d, *J* = 6.8 Hz, 3H).] *syn*-Diastereomer (minor): [¹H NMR (400 MHz, CDCl₃) δ 7.99 – 7.95 (m, 2H), 7.51 – 7.44 (m, 2H), 7.42 – 7.37 (m, 2H), 7.34 – 7.30 (m, 2H), 7.26 – 7.20 (m, 1H), 6.33 (d, *J* = 16.0 Hz, 1H), 5.88 (dd, *J* = 16.0, 8.4 Hz, 1H), 3.12 – 2.98 (m, 1H), 1.59 (s, 3H), 1.07 (d, *J* = 6.9 Hz, 3H).] (1,4)-Regioisomer (minor): [¹H NMR (400 MHz, CDCl₃) δ 7.96 – 7.90 (m, 2H), 7.84 – 7.77 (m, 2H), 7.44 – 7.41 (m, 2H), 7.34 – 7.27 (m, 1H), 7.14 – 7.12 (m, 2H), 5.78 – 5.57 (m, 2H), 3.66 (d, *J* = 9.8 Hz, 1H), 2.24 (s, 3H), 1.76 (dd, *J* = 6.4, 1.5 Hz, 3H).] ¹³C NMR (151 MHz, CDCl₃) δ 181.0, 165.5, 163.2, 161.6, 160.3, 160.0, 137.6, 133.2, 133.1, 132.9, 132.8, 131.7, 129.1, 129.1, 128.9, 128.9, 128.5, 128.1, 127.9 (dd, *J* = 20.7, 8.0 Hz), 127.1, 127.1, 126.6, 126.0, 115.6 (dd, *J* = 21.6, 10.7 Hz), 109.2, 72.5, 47.0, 45.1, 22.8, 15.9, 15.1, 14.0. IR (v/cm⁻¹): 3028 (m), 2976 (m), 2933 (m), 2873 (w), 1823 (m), 1783 (s), 1653 (m), 1490 (m), 1403 (w), 1311 (m), 1171 (m), 1092 (m), 1000 (m), 967 (m), 840 (m). HRMS (ES⁺) [M–H]⁺ calcd for C₂₀H₁₉ClNO₂⁺ 340.1104, found: 340.1099.

■ General procedure for hydrolysis of oxazolone products in Table 4 (29-31):

An 8 mL reaction vial with a stir bar was charged with the oxazolone and potassium carbonate with no effort to exclude oxygen or water. The reaction was solvated with wet methanol and the headspace purged with N_2 for 5 minutes. The reaction was sealed and allowed to stir at room temperature for a minimum of 2 hours before being concentrated by rotary evaporation to remove the solvent. The resulting powder was purified by SiO₂ gel chromatography to yield the hydrolyzed product.

■ Procedure and characterization for hydrolysis of oxazolone products in Table 4: Synthesis of methyl (*E*)-2-benzamido-2,3-dimethyl-5-phenylpent-4-enoate (29).



Following the general procedure for hydrolysis, 4-methyl-2-phenyl-4-((*E*)-4-phenylbut-3-en-2-yl)oxazol-5(4H)-one (12.1 mg, 0.0396 mmol, 19:1 dr) and K₂CO₃ (27.4 mg, 0.198 mmol, 5 equiv) were solvated in methanol (400 μ L) and allowed to stir at 22 °C for 2 h. The solution was concentrated to an off white solid which was purified by SiO₂ gel column chromatography (10:1 Hex/Et₂O) to afford **29** (11.1 mg, 0.0344 mmol, 87% yield, 20:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 7.73 – 7.70 (m, 2H), 7.48 – 7.45 (m, 1H), 7.39 – 7.37 (m, 2H), 7.37 – 7.33 (m, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H), 6.84 (s, 1H), 6.52 (d, J = 15.8 Hz, 1H), 6.17 (dd, J = 15.8, 9.3 Hz, 1H), 3.79 (s, 3H), 3.00 (dq, J = 14.0, 7.0 Hz, 1H), 1.80 (s, 3H), 1.22 (d, J = 7.0 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 173.5, 166.9, 136.9, 134.8, 132.6, 131.7, 130.3, 128.7, 128.7, 127.8, 127.0, 126.5, 62.8, 52.6, 45.3, 20.8, 15.9. **IR** (v/cm⁻¹): 3410 (br, m), 3334 (br, m), 3027 (m), 2975 (m), 2949 (m), 1739 (s), 1653 (s), 1521 (s), 1488 (m), 1373 (m), 1263 (m), 1127 (m), 970 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₁H₂₄NO₃⁺ 338.1756, found: 338.1750.

Synthesis of methyl (E)-2-benzamido-5-(furan-2-yl)-2-isobutyl-3-methylpent-4-enoate (30).



Following the general procedure for hydrolysis, 4-((E)-4-(furan-2-yl)but-3-en-2-yl)-4-isobutyl-2-phenyloxazol-5(4H)-one (8.5 mg, 0.025 mmol, 9:1 dr) and K₂CO₃ (17.4 mg, 0.126 mmol, 5 equiv) were solvated in methanol (2 mL) and allowed to stir at 22 °C for 2 h. The solution was concentrated to an off white solid which was purified by SiO₂ gel column chromatography (10:1 Hex/Et₂O) to afford **30** (8.3 mg, 0.0248 mmol, 89% yield, >20:1 dr) as a colorless oil.

¹**H** NMR (600 MHz, CDCl₃) δ 7.78 – 7.74 (m, 2H), 7.49 (t, *J* = 7.4 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 2H), 7.37 (s, 1H), 7.28 (d, *J* = 1.2 Hz, 1H), 6.30 (dd, *J* = 3.2, 1.8 Hz, 1H), 6.18 (d, *J* = 15.7 Hz, 1H), 6.07 (d, *J* = 3.2 Hz, 1H), 5.94 (dd, *J* = 15.7, 9.1 Hz, 1H), 3.84 (s, 3H), 3.57 – 3.49 (m, 1H), 2.73 (dd, *J* = 14.1, 4.3 Hz, 1H), 1.95 (dd, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, *J* = 14.0, 9.0 Hz, 1H), 1.68 – 1.55 (m, 1H), 1.21 (d, J = 14.0, 9.0 Hz, 1H), 1.51 (d, J = 14.0, 9.0 H

7.0 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H), 0.77 (d, J = 6.6 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 174.5, 166.6, 152.7, 141.8, 135.6, 131.5, 129.3, 128.7, 127.0, 120.4, 111.2, 107.4, 67.2, 52.7, 43.1, 41.0, 25.2, 24.3, 22.0, 15.8. **IR** (v/cm⁻¹): 3413 (w), 2962 (s), 2923 (m), 2866 (w), 1731 (m), 1669 (s), 1508 (m), 1488 (w), 1260 (s), 1095 (br, s), 1021 (br, s), 799 (s). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₂H₂₈NO₄⁺ 370.2018, found: 370.2013.

Synthesis of methyl methyl (*E*)-2-benzamido-3-methyl-2-propyltridec-4-enoate (A).



Following the general procedure for hydrolysis, 4-((E)-dodec-3-en-2-yl)-2-phenyl-4propyloxazol-5(4H)-one (17.1 mg, 0.0463 mmol, 9:1 dr) and K₂CO₃ (320 mg, 2.31 mmol, 5 equiv) were solvated in methanol (4 mL) and allowed to stir at 22 °C for 18 h. The solution was concentrated to an off white solid which was purified by SiO₂ gel column chromatography (5:1 Hex/Et₂O) to afford **S-A** (14.9 mg, 0.0371 mmol, 80% yield, 9:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 7.77 – 7.75 (m, 2H), 7.50 – 7.47 (m, 1H), 7.44 – 7.41 (m, 2H), 7.09 (s, 1H), 5.51 – 5.43 (m, 1H), 5.26 (dd, J = 15.2, 9.1 Hz, 1H), 3.79 (s, 3H), 3.12 (dq, J = 14.2, 7.1 Hz, 1H), 2.54 (ddd, J = 13.8, 12.1, 4.6 Hz, 1H), 2.10 (ddd, J = 13.8, 12.1, 4.5 Hz, 1H), 1.96 – 1.92 (m, 2H), 1.38 – 1.14 (m, 14H), 1.10 (d, J = 7.0 Hz, 3H), 0.90 (t, J = 7.3 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 174.02, 166.20, 135.41, 133.46, 131.48, 130.64, 128.66, 126.95, 67.31, 52.61, 42.29, 34.06, 32.68, 32.03, 29.68, 29.59, 29.39, 29.24, 22.81, 17.96, 16.05, 14.27, 14.25. **IR** (v/cm⁻¹): 3415 (m), 2956 (m), 2925 (s), 2854 (m), 1730 (s), 1669 (s), 1515 (m), 1486 (w), 1232 (m), 971 (w). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₅H₃₉NO₃⁺ 402.3008, found: 402.3006.

Synthesis of methyl (*E*)-2-benzamido-2-isobutyl-3-methyltridec-4-enoate (31).



Following the general procedure for hydrolysis, 4-((E)-dodec-3-en-2-yl)-4-isobutyl-2-phenyloxazol-5(4H)-one (9.2 mg, 0.024 mmol, 11:1 dr) and K₂CO₃ (16.6 mg, 0.120 mmol, 5 equiv) were solvated in methanol (2 mL) and allowed to stir at 22 °C for 2 h. The solution was concentrated to an off white solid which was purified by SiO₂ gel column chromatography (20:1 Hex/Et₂O) to afford**31**(8.4 mg, 0.020 mmol, 84% yield, 10:1 dr) as a colorless oil.

¹**H** NMR (600 MHz, CDCl₃) δ 7.78 – 7.75 (m, 2H), 7.49 (t, *J* = 7.4 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 2H), 7.29 (s, 1H), 5.45 – 5.39 (m, 1H), 5.17 (dd, *J* = 15.2, 9.0 Hz, 1H), 3.80 (s, 3H), 3.31 – 3.25 (m, 1H), 2.63 (dd, *J* = 14.1, 4.2 Hz, 1H), 1.96 (dd, *J* = 14.1, 9.0 Hz, 1H), 1.92 – 1.89 (m, 2H), 1.64-1.59 (m, 1H), 1.28 – 1.13 (br m, 12H), 1.10 (d, *J* = 7.0 Hz, 3H), 0.92 (d, *J* = 6.7 Hz, 3H),

0.87 (t, J = 7.2 Hz, 3H), 0.76 (d, J = 6.6 Hz, 3H). ¹³C NMR (151 MHz, CDCl₃) δ 174.7, 166.3, 135.7, 133.4, 131.4, 130.4, 128.7, 126.9, 66.9, 52.5, 42.7, 40.8, 32.7, 32.0, 29.6, 29.6, 29.4, 29.2, 25.1, 24.4, 22.8, 22.1, 15.9, 14.3. **IR** (v/cm⁻¹): 3416 (br, s), 2955 (m), 2925 (s), 2854 (m), 1726 (m), 1669 (s), 1514 (m), 1485 (m), 1366 (m), 1235 (m), 970 (w). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₆H₄₂NO₃⁺ 416.3165, found: 416.3160.

■ Procedure and characterization for the functionalization of oxazolone products in Table 5 (32-33):

Synthesis of (*E*)-2-benzamido-3-methyl-2-phenethyl-5-(o-tolyl)pent-4-enoic acid (32).



To an 8 mL vial was added 4-phenethyl-2-phenyl-4-(*E*-4-(o-tolyl)but-3-en-2-yl)oxazol-5(4H)one (6.4 mg, 0.016 mmol, 10:1 dr), dioxane (1 mL) and 1M HCl (1 mL). The reaction was sealed with a septum cap and the headspace flushed with N₂ before being heated to 80 °C. The reaction was allowed to stir at 80°C for 8 h before being cooled to room temperature and extracted three times with EtOAc (1 mL). The organic layers were dried with Na₂SO₄ and filtered before being concentrated. The resulting oil was dried by rotoray evaporation with additional chloroform to remove residual dioxane to yield **32** as a clear film (5.9 mg, 0.014 mmol, 87% yield, >20:1 dr). The product required no further purification.

¹**H NMR** (600 MHz, CDCl₃) δ 7.77 – 7.75 (m, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.7 Hz, 2H), 7.39 – 7.38 (m, 1H), 7.24 (d, J = 7.4 Hz, 2H), 7.20 (d, J = 7.0 Hz, 2H), 7.18 – 7.14 (m, 2H), 7.13 – 7.09 (m, 2H), 7.08 – 7.06 (m, 1H), 6.66 (d, J = 15.5 Hz, 1H), 6.00 (dd, J = 15.5, 9.3 Hz, 1H), 3.51 (dq, J = 14.0, 7.0 Hz, 1H), 3.06 – 2.97 (m, 1H), 2.75 – 2.67 (m, 1H), 2.56 – 2.47 (m, 2H), 2.16 (s, 3H), 1.29 (d, J = 7.0 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 176.1, 167.3, 141.3, 136.3, 135.4, 134.7, 132.0, 131.6, 130.6, 130.3, 128.9, 128.8, 128.6, 127.6, 127.0, 126.2, 126.2, 126.1, 67.8, 43.2, 34.3, 31.2, 19.8, 15.9. **IR** (v/cm⁻¹): 3384 (br, m), 3220 (br, m), 3062 (w), 3027 (m), 2972 (m), 2930 (m), 2561 (br, m), 1715 (s), 1625 (s), 1523 (s), 1488 (m), 1455 (w), 1231 (m), 1192 (m), 1122 (w), 967 (m), 909 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₅H₄₀NO₄⁺ 428.2226, found: 428.2237.

Synthesis of methyl 2-benzamido-2-(1-(3-octyloxiran-2-yl)ethyl)pentanoate (33).



To an 8 mL vial was added 4-((E)-dodec-3-en-2-yl)-2-phenyl-4-propyloxazol-5(4H)-one (8.9 mg, 0.022 mmol, 9:1 dr) and *meta*-chloroperoxybenzoic acid 50-55% by weight (7.6 mg, 0.22 mmol, 1 equiv). The headspace was flushed with N₂ and the reaction solvated with dry benzene

(500 μ L), the reaction sealed and allowed to stir at 22 °C for 18 h. The solution was concentrated to an oily solid which was purified by SiO₂ gel column chromatography (8:1 Hex/EtOAc to 4:1 Hex/EtOAc) to afford **33** (5.4 mg, 0.013 mmol, 58% yield, 9:1 dr) as a colorless oil.

¹**H NMR** (600 MHz, CDCl₃) δ 7.82 – 7.79 (m, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.42 (s, 1H), 3.85 (s, 3H), 2.86 (ddd, J = 13.5, 12.0, 4.6 Hz, 1H), 2.82 – 2.80 (m, 1H), 2.72 (dd, J = 7.8, 2.2 Hz, 1H), 2.39 (dt, J = 14.5, 7.1 Hz, 1H), 1.93 – 1.86 (m, 1H), 1.55 – 1.50 (m, 1H), 1.47 – 1.38 (m, 1H), 1.38 – 1.15 (m, 14H), 1.07 (d, J = 7.0 Hz, 3H), 1.00 – 0.94 (m, 1H), 0.90 (t, J = 7.2 Hz, 3H), 0.87 (t, J = 7.1 Hz, 3H). ¹³**C NMR** (151 MHz, CDCl₃) δ 174.6, 166.2, 135.1, 131.8, 128.8, 127.0, 67.2, 60.0, 59.8, 53.3, 42.8, 34.3, 32.2, 32.0, 29.6, 29.6, 29.3, 26.0, 22.8, 18.0, 14.3, 14.1, 12.6. IR (v/cm⁻¹): 3410 (br, m), 2960 (w), 2928 (s), 2855 (m), 1732 (s), 1671 (s), 1518 (s), 1487 (m), 1271 (w), 1234 (m). **HRMS** (ES⁺) [M–H]⁺ calcd for C₂₅H₄₀NO₄⁺ 418.2957, found: 418.2951.

■ General procedure for exploring the effect of the alcohol additive on hydroalkylation Table 6:



Following the general procedure for the Rh(I) catalyzed hydroalkylation of dienes with oxazalones, (CDC)-Rh(I)styrene BAr $_4^F$ 1 (8.1 mg, 0.005 mmol), LiPF₆ (0.8 mg, 0.005 mmol), and phenylbutadiene (13.0 mg, 0.100 mmol) were combined in the glove box, solvated with toluene (200 µL, 0.5 M) and allowed to stir at 22 °C for 10 minutes. To this solution, 4-methyl-2-phenyloxazol-5(4H)-one (26.3 mg, 0.150 mmol) was added. The reaction was sealed with a Teflon® septum cap and removed from the glove box. To this reaction the appropriate alcohol additive was added either: 1) Inside the glove [eg: menthol (9.4 mg, 0.06 mmol), (R)-BINOL (17.0 mg, 0.060 mmol), TADDOL-P(O)OH (31.7 mg, 0.060 mmol), (S,S)-hydrobenzoin (12.9 mg, 0.060 mmol) or (S,S)-diphenylethylenediamine (12.7 mg, 0.060 mmol)], or 2) Outside the glove box via syringe after sparging the alcohol with N_2 [eg: methanol (2.4 μ L, 0.060 mmol), isopropanol (4.6 µL, 0.060 mmol), tert-butanol (5.7 µL, 0.060 mmol)]. The reaction were allowed to stir at 50 °C for 18 h. The reaction was cooled to room temperature and 5 µL of hexamethyldisiloxane added as an internal standard. The reaction was diluted with CDCl₃ and both the conversion and diastereoselectivity analyzed by NMR spectroscopy. Reactions with a chiral additive were purified by SiO₂ gel column chromatography (20:1 Hex/Et2O) before being assayed on an Agilent 1220 LC System with a Daicel ChiralPak IA column (99:1 Hexanes/Isopropanol, 1 mL/min, 210 nm).

	Ae + A 3 (CDC)-Rh 1 (5 mo LiPF ₆ (5 mol % additive PhMe, 50 °C, 1	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \\ \end{array} \\ $	Ph
entry	additive; mol %	NMR Yield (%) ^a ; dr ^b	% ee
1	MeOH; 60	68; 7:1	-
2	iPrOH; 60	84; 19:1	-
3	tBuOH; 60	87; 12:1	-
4	Menthol; 60	62; >20:1	0
5	(R)-BINOL; 60	56; 15:1	0
6	(S,S)-hydrobenzoin; 60	53; 10:1	0
7	$\stackrel{PD}{Me} \xrightarrow{O} \xrightarrow{V} \stackrel{O}{\downarrow} \stackrel{O}{\downarrow} \stackrel{O}{OH} ; 60$ $\stackrel{Ph}{Ph} \stackrel{Ph}{Ph}$	13; 2:1	0
8	(S,S)-diphenylethylenediamine; 10	27; 18:1	0

Table 6. Exploring the Influence of the Alcohol on Reaction Efficiency and Selectivity.

^{*a*}Values determined by analysis of 500 or 600 MHz ¹H NMR spectra of unpurified mixtures with trimethylsilyl ether as an internal standard. ^{*b*}NMR Yield reported for conversion to the *cis*- and *trans*-**4** products.

Table 1. Survey of Conditions for (CDC)-Rh-Catalyzed Diastereo- and Siteselective Hydroalkylation of 1,3 Diene $3.^{a}$

		(CDC)-Rh 1 (5 Activator (x i alcoho	5 mol %) mol %) I O	O Me Ph
م Ph	2 3	solvent, 50 °	C,18h 🗡 Ph	-≕N 4
entry	activator; mol %	solvent	alcohol ^d	yield (%) <i>^c;</i> dr ^b
1	AgCl; 5	PhMe	-	0; -
2	LiBF ₄ ; 5	PhMe	-	8; 4:1
3	LiPF ₆ ; 5	PhMe	-	17; 10:1
4	LiPF ₆ ; 5	PhCl	-	21; 6:1
5	LiPF ₆ ; 5	THF	-	21; 4:1
6	LiPF ₆ ; 5	DCM	-	20; 3:1
7	LiPF ₆ ; 5	PhMe	MeOH	26; 3:1
8	LiPF ₆ ; 5	PhMe	ⁱ PrOH	85; 19:1
9	LiPF ₆ ; 5	PhMe	^t BuOH	29; 5:1
10 <i>e</i>	LiPF ₆ ; 5	PhMe	ⁱ PrOH	0; -

^{*a*}All reactions performed under N₂ atm. ^{*b*}Values determined by analysis of 400 or 600 MHz ¹H NMR spectra of unpurified mixtures with trimethylsilyl ether as an internal standard. ^{*c*}Yields of purified products are an average of two runs. ^{*d*}A solvent ratio of 40:1 PhMe:alcohol used. ^{*e*}Reaction run with [Rh(cod)Cl]₂ as catalyst with NaBAr^F₄ additive.

References:

(1) Lishchynskyi, A.; Muñiz, K. Chem. – Eur. J. 2012, 18 (8), 2212.

(2) Preuß, T.; Saak, W.; Doye, S. Chem. – Eur. J. 2013, 19 (12), 3833.

- (3) Macreadie, I. G.; Avery, T. D.; Robinson, T. V.; Macreadie, P.; Barraclough, M.; Taylor, D. K.; Tiekink, E. R. T. *Tetrahedron* **2008**, *64* (7), 1225.
- (4) Galvani, G.; Lett, R.; Kouklovsky, C. Chem. Eur. J. 2013, 19 (46), 15604.
- (5) Townsend, E. M.; Schrock, R. R.; Hoveyda, A. H. J. Am. Chem. Soc. 2012, 134 (28), 11334.
- (6) Weber, M.; Jautze, S.; Frey, W.; Peters, R. J. Am. Chem. Soc. 2010, 132 (35), 12222.
- (7) Esteban, F.; Alfaro, R.; Yuste, F.; Parra, A.; Ruano, J. L. G.; Alemán, J. *Eur. J. Org. Chem.* **2014**, *2014* (7), 1395.
- (8) Metrano, A. J.; Miller, S. J. J. Org. Chem. 2014, 79 (4), 1542.
- (9) Melhado, A. D.; Luparia, M.; Toste, F. D. J. Am. Chem. Soc. 2007, 129 (42), 12638.
- (10) Yakelis, N. A.; Bergman, R. G. Organometallics 2005, 24 (14), 3579.
- (11) Goldfogel, M. J.; Roberts, C. C.; Meek, S. J. J. Am. Chem. Soc. 2014, 136 (17), 6227.
- (12) Roberts, C. C.; Matías, D. M.; Goldfogel, M. J.; Meek, S. J. J. Am. Chem. Soc. 2015, 137 (20), 6488.
- (13) Voituriez, A.; Charette, A. B. Adv. Synth. Catal. 2006, 348 (16-17), 2363.





















































































































